CRBU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRBU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Caribou Biosciences's Trailing 12-Month Free Cash Flow is $-144.71 Mil, and Market Cap is $71.20 Mil. Therefore, Caribou Biosciences's FCF Yield % for today is -203.25%.
The historical rank and industry rank for Caribou Biosciences's FCF Yield % or its related term are showing as below:
During the past 6 years, the highest FCF Yield % of Caribou Biosciences was -0.86%. The lowest was -207.35%. And the median was -23.40%.
Caribou Biosciences's FCF Margin % for the quarter that ended in Dec. 2024 was -1,732.69%.
The historical data trend for Caribou Biosciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
FCF Yield % | Get a 7-Day Free Trial | - | -3.92 | -25.58 | -20.70 | -98.52 |
Caribou Biosciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-18.67 | -34.60 | -95.10 | -75.13 | -98.00 |
For the Biotechnology subindustry, Caribou Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Caribou Biosciences's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -144.705 | / | 146.88261 | |
= | -98.52% |
Caribou Biosciences's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -35.988 | * | 4 | / | 146.88261 | |
= | -98.00% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Caribou Biosciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rachel E. Haurwitz | director, officer: See Remarks | C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Ruhi Ahmad Khan | officer: Chief Business Officer | C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Barbara G Mcclung | officer: See Remarks | CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Steven Kanner | officer: See Remarks | CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Syed Ali-aamir Rizvi | officer: Chief Medical Officer | C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Ryan Fischesser | officer: See Remarks | CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
David Lee Johnson | director | C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080 |
Dara Richardson-heron | director | C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710 |
Ran Zheng | director | 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Nancy Whiting | director | 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
Natalie Sacks | director | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Andrew Guggenhime | director | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Jason O'byrne | officer: See Remarks | CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710 |
From GuruFocus
By PRNewswire • 02-24-2025
By Marketwired • 02-13-2025
By PRNewswire • 02-20-2025
By Marketwired • 02-24-2025
By Marketwired • 02-13-2025
By Marketwired • 02-18-2025
By Marketwired • 03-10-2025
By PRNewswire • 02-14-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.